Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Improve first-line care for KRAS G12C–mutated advanced NSCLC through timely biomarker testing, personalized treatment strategy, and clinical trial referral.

